TheStreet Ratings

10 Best Biotech Stocks for 2016 - Top Stocks - TheStreet Ratings

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology

Source: TheStreet Ratings

Best Investments for

Biotechnology News

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.
1/20/17 8:17AM
CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.
1/18/17 7:53AM
The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.
1/17/17 4:19PM
There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.
1/10/17 10:33AM
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
1/9/17 3:55PM
Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.
1/9/17 1:15PM
Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.
1/8/17 5:01PM
Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.
1/7/17 10:13AM
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
1/6/17 5:50AM
RBC Capital Markets biotech analyst Michael Yee takes a swivel-headed approach to fundamental research.
1/5/17 11:04AM
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
1/5/17 6:21AM
The Lexington, Mass.-based biotech company said Tuesday that an experimental treatment for glaucoma failed to fully demonstrate superiority over placebo in a phase III clinical trial.
1/3/17 8:42AM
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
1/3/17 6:35AM
TheStreet's biotech columnist offers his own report card on biotech stocks.
12/22/16 11:20AM
A look back at the year's worth of Adam Feuerstein's biotech tweets.
12/22/16 9:24AM